ASCO 2020：11项东亚研究入选口头报告，17项Poster报告

受全球新冠疫情受到影响，原定于5年末29日~6年末2日在波士顿举行的美国诊疗学会（ASCO）年会今年将首次以线上表达方式举办，这是目前最大规模的线上盛会。今天，全会的简短题目披露，共103个sessions，中所国共有11项研究者入围口头报告，17项入围Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

硫替尼或帕尔马替尼加卡培他滨用做HER2+前列腺癌乳腺肿瘤（PHOEBE）：一项III期随机检验。

大舞台：前列腺癌乳腺肿瘤

原作者：中所国医学科学院公立医院徐兵河讲师、马飞讲师，浙江大学附设公立医院胡夕春讲师等

简短号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可治疗三中性乳腺肿瘤基准治疗法后卡培他滨维持节拍化学疗法的III期检验（SYSUCC-001）。

大舞台：乳腺肿瘤—范围内/范围/基本功能治疗法

原作者：中所山大学防治中所心王树森讲师等

简短号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用前列腺癌脑的性状特征来预测脑脊液中所气化DNA检测的概率: 新工具抵抗据说竞争对手

大舞台：新工具解决据说解决办法

原作者：李美芹 李德兰等

简短号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

利诺非尼对马利拉非尼作为早期肝细胞核肿瘤的一线治疗法：一项全站字句、随机、多中所心II/III期检验。

大舞台：肾脏肿瘤—腹腔膀胱、肾上腺和实无

原作者：复旦大学特罗斯季亚涅齐公立医院毕锋讲师、中所国当权者解放军朝阳公立医院秦叔逵讲师等

简短号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中所国早期肝肿瘤症状阿帕替尼二线治疗法：一项随机、诊疗实验依此、双盲III期研究者

大舞台：肾脏肿瘤—腹腔膀胱、肾上腺和实无

原作者：中所国当权者解放军朝阳公立医院秦叔逵讲师、复旦大学特罗斯季亚涅齐公立医院李秋讲师等

简短号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

早期风湿热卵巢肿瘤二次细胞核减灭术的一项随机III期检验：SOC1 / SGOG-OV2。

研讨：医学肿瘤症

原作者：浙江大学附设中所山公立医院臧荣余讲师等

简短：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈肿瘤根治性子宫切除术后基本功能治疗法中所的序贯放化学疗法对比实质上前列腺癌或同步放化学疗法（STARS研究者）：一项随机、依此、全站字句的III期检验。

全会：医学肿瘤症

原作者：中所山大学防治中所心黄鹤讲师、刘继红讲师等

简短号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：基本功能吉非替尼对比化学疗法用做可切除的EGFR特异性的N1-N2期NSCLC-随机III期诊疗检验的最终总体生存归纳。

研讨：肺肿瘤—非小细胞核范围内-范围/小细胞核/其他臀部

原作者：广东省当权者公立医院吴一龙讲师等

简短号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR特异性唯转移非小细胞核肺肿瘤症状一线半胱氨酸激酶类似物倡议或不倡议积极前线范围内前列腺癌：III期全站字句诊疗随机检验（SINDAS）的前期结果（NCT02893332）。

研讨：肺肿瘤-非小细胞核转移

原作者：四川省当权者公立医院曾铭讲师等

简短：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对就其幸存者-1（PD-1）的人源化IgG4类似物倡议阿昔替尼用做前列腺癌皮肤乳癌症状的Ib期研究者的总生存期和生物标志物归纳。

研讨：乳癌/皮肤肿瘤

原作者：中国大学公立医院郭军、盛锡楠讲师等

简短：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全性和结果：通用CAR-T细胞核首次人体检验治疗法复发/难治性T细胞核急性淋巴细胞核白血病（r/r T-ALL）的安全性和。全会：开发中所的治疗法应用-免疫治疗法。原作者：王岂料等简短：3013名片：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在早期膀胱粒状细胞核肿瘤症状中所的广泛应用：一项随机的全站字句II期检验（ORIENT-2）。全会：肾脏肿瘤-腹腔膀胱肿瘤、肾上腺肿瘤和实无道肿瘤原作者：徐建明讲师等简短：4511名片：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D抗原CAR-T细胞核对子叶母细胞核瘤的根治性治疗法全会：中所枢神经系统原作者：代红久、孙斌、杨东、徐晖、朱小金、魏佳、姚旭东简短：2522名片。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在早期错配修复缺陷症状中所的广泛应用全会：开发中所的治疗法学-免疫治疗法原作者：沈琳讲师等简短：3021名片。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART治疗法复发/难治性ACUTE淋巴细胞核白血病/淋巴瘤的尚属人体诊疗检验全会: 开发性治疗法学-免疫治疗法原作者简介：张明志，新兴镇等简短：3026名片: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 利是替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）倡议广泛应用做早期实体瘤症状的Ib期研究者全会：发展性治疗法学--分子特异性药物和生物学原作者：龚继芳，沈琳讲师等简短：3523名片：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin倡议紫杉醇和nedaplatin治疗法风湿热或前列腺癌膀胱粒状细胞核肿瘤（ESCC）症状的II期研究者。全会：肾脏肿瘤-腹腔膀胱、肾上腺和实无道肿瘤的研究者原作者：王志强，李玉红，王德申，王凤华，任超，谭琼 王志强、李玉红、王德深、王凤华、任超、谭琼简短：4522名片：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全会：肾脏肿瘤-腹腔膀胱肿瘤、肾上腺肿瘤和实无管肿瘤的二线治疗法原作者：宋艳等简短：4524名片：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体环状RNA特征向量用做初始活检时检测高等级肿瘤的尿液外体环状RNA特征向量：一项多中所心的回顾性研究者全会：消化系统生殖器官肿瘤症---肿瘤、睾丸肿瘤和肿瘤原作者简介：Liaoyuan Li等简短：5522名片。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 范围内早期宫颈肿瘤并发化学疗法后的基本功能化学疗法全会: 医学肿瘤症原作者简介： 李珉珉等简短：6031名片：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼治疗法甲状腺子叶性肿瘤的关联性：基于ALTER01031检验的归纳。会话：外周原作者：天津市公立医院高明讲师简短：6526名片。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼治疗法后症状整部的受到影响: ALTER01031的亚组归纳全会：外周原作者：天津市公立医院高明讲师简短：6527名片。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA归纳预测I-IIIA期非小细胞核肺肿瘤（NSCLC）症状术后复发: GASTO1035和GASTO1018的结果全会：肺肿瘤-非小细胞核范围内-范围性/小细胞核/小细胞核/其他胸科肿瘤症原作者：Si-Yu Wang等简短：9023名片：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞核肺肿瘤（NSCLC）中所EGFR半胱氨酸激酶类似物的新型耐药系统全会:肺肿瘤-非小细胞核前列腺癌肺肿瘤原作者简介：姚昕，金小妹，满宇，欧西厢记，华宝，薛武，杨少，范敏 姚昕、金小妹、满宇、欧西厢记、华宝、薛武、杨绍、范敏简短：9528名片：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1检验中所早期乳癌总生存的替代终点全会：乳癌/皮肤肿瘤原作者：聂润聪，袁书强，李元芳，陈英波，周志伟 聂润聪、袁书强、李元芳、陈英波、周志伟简短：10030名片：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼治疗法复发或前列腺癌原发性恶性肩胛骨症状的II期研究者全会： 性疾病原作者：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶简短：11525名片。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步赞赏安罗替尼在早期性疾病症状多线治疗法中所的安全性和。全会：性疾病原作者：姚伟涛，王家强，张鹏，王欣，杜新辉，田志浩，牛晓颖 姚伟涛、王家强、张鹏、王鑫、杜鑫辉、田志超、牛晓英简短：11526名片：414